We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Scales Technology-Enabled, Vertically Integrated Care
Read MoreHide Full Article
Key Takeaways
HIMS acquired MedisourceRx to expand its compounding and vertically integrated care capabilities.
HIMS launched a GLP-1 weight loss program featuring semaglutide and real-time provider oversight.
Hims & Hers is expanding into hormone health with exclusive and customized treatments for men and women.
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , operates an integrated, proprietary technology platform that manages the full journey from customer discovery to ongoing clinical management. The platform connects consumers to a distributed provider network, a proprietary electronic medical record, digital prescribing, and in-house mail-order pharmacies, enabling subscription-based care across categories such as sexual health, dermatology, mental health and weight management. In 2024, Hims & Hers acquired MedisourceRx, a licensed 503B compounding outsourcing facility that compounds products primarily for its customers, further strengthening its vertically integrated care delivery and fulfillment infrastructure and supporting efficient scaling of personalized treatments. This infrastructure underpins a series of recent launches and category expansions.
In weight management, Hims & Hers offers a digitally delivered GLP-1 program, including compounded and branded semaglutide, with app-based engagement and data-driven provider oversight. The same platform supports new hormone-health offerings — a men’s health category centered on low-testosterone care, including an exclusive planned launch of KYZATREX oral testosterone and customized combinations like enclomiphene with tadalafil, as well as a Hers menopause and perimenopause specialty built around tailored treatment plans and ongoing provider adjustments. Together, these initiatives illustrate how HIMS’ technology and vertically integrated operations enable rapid rollout of new, recurring care programs at scale.
TDOC & AMWL’s Enterprise Virtual Care Platforms
Teladoc Health, Inc.’s (TDOC - Free Report) core platform is a highly scalable, integrated, API-driven virtual care system that connects patients, clinicians, devices and partner applications to deliver primary, chronic and mental health services globally. Teladoc Health uses this proprietary technology platform to orchestrate care across health plans, employers, hospitals and consumers at high visit volumes. Recently, Teladoc Health expanded its AI-enabled Clarity monitoring solution with a workplace-safety capability that analyzes care-site signals and supports rapid intervention in hospitals and health systems.
American Well Corporation’s (AMWL - Free Report) , popularly known as Amwell, Converge platform is a cloud-based, enterprise software system that unifies virtual, automated and in-person care into a single configurable infrastructure for health plans, health systems and other clients. Amwell designed the Converge platform to be future-ready, scalable, secure and integrated with third-party healthcare software. Recently, Amwell’s technology helped the U.S. Defense Health Agency extend its Digital First program, enabling hybrid care for the Military Health System with connected, seamless in-person and virtual experiences.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 69.8% year to date, outperforming the industry’s growth of 19.2%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 3.4X is lower than the industry’s average of 5.5X, but is higher than its three-year median of 2.5X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests an 81.5% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
Image: Bigstock
Hims & Hers Scales Technology-Enabled, Vertically Integrated Care
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , operates an integrated, proprietary technology platform that manages the full journey from customer discovery to ongoing clinical management. The platform connects consumers to a distributed provider network, a proprietary electronic medical record, digital prescribing, and in-house mail-order pharmacies, enabling subscription-based care across categories such as sexual health, dermatology, mental health and weight management. In 2024, Hims & Hers acquired MedisourceRx, a licensed 503B compounding outsourcing facility that compounds products primarily for its customers, further strengthening its vertically integrated care delivery and fulfillment infrastructure and supporting efficient scaling of personalized treatments. This infrastructure underpins a series of recent launches and category expansions.
In weight management, Hims & Hers offers a digitally delivered GLP-1 program, including compounded and branded semaglutide, with app-based engagement and data-driven provider oversight. The same platform supports new hormone-health offerings — a men’s health category centered on low-testosterone care, including an exclusive planned launch of KYZATREX oral testosterone and customized combinations like enclomiphene with tadalafil, as well as a Hers menopause and perimenopause specialty built around tailored treatment plans and ongoing provider adjustments. Together, these initiatives illustrate how HIMS’ technology and vertically integrated operations enable rapid rollout of new, recurring care programs at scale.
TDOC & AMWL’s Enterprise Virtual Care Platforms
Teladoc Health, Inc.’s (TDOC - Free Report) core platform is a highly scalable, integrated, API-driven virtual care system that connects patients, clinicians, devices and partner applications to deliver primary, chronic and mental health services globally. Teladoc Health uses this proprietary technology platform to orchestrate care across health plans, employers, hospitals and consumers at high visit volumes. Recently, Teladoc Health expanded its AI-enabled Clarity monitoring solution with a workplace-safety capability that analyzes care-site signals and supports rapid intervention in hospitals and health systems.
American Well Corporation’s (AMWL - Free Report) , popularly known as Amwell, Converge platform is a cloud-based, enterprise software system that unifies virtual, automated and in-person care into a single configurable infrastructure for health plans, health systems and other clients. Amwell designed the Converge platform to be future-ready, scalable, secure and integrated with third-party healthcare software. Recently, Amwell’s technology helped the U.S. Defense Health Agency extend its Digital First program, enabling hybrid care for the Military Health System with connected, seamless in-person and virtual experiences.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 69.8% year to date, outperforming the industry’s growth of 19.2%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 3.4X is lower than the industry’s average of 5.5X, but is higher than its three-year median of 2.5X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests an 81.5% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.